Biosynth Expands Berlin Site with a New Commercial Bioconjugation Suite
Biosynth, a leading developer and supplier of critical raw materials and services for life sciences and diagnostics, is pleased to announce the opening of its expanded GMP bioconjugation facility at its existing Berlin site. This strategic expansion significantly enhances Biosynth's specialized manufacturing capabilities in conjugate vaccines and conjugate drugs, activated PEGs, and polymer-based drug delivery excipients as part of its global manufacturing network.
Biosynth Names Matt Gunnison as CEO, Kieran Murphy Appointed as Chairman
Biosynth, a global supplier of critical raw materials and services to the life sciences industry, today announced that its Board of Directors has appointed Matt Gunnison as the company's new Chief Executive Officer and a member of the Board of Directors, effective immediately. The Board has also appointed Kieran Murphy as Chairman, effective as of the same date.
Biosynth’s Unique Online Custom Peptide Toolset Completed with Full Order Tracking and QC Data Portal
Biosynth, a supplier of critical raw materials and services for diagnostics, vaccines, and pharmaceuticals, is pleased to announce the next step in its custom peptide revolution.
Biosynth extends its offering to multi-kilogram GMP peptide synthesis through the acquisition of Pepceuticals
Biosynth, a supplier of critical materials to the life science industry, is pleased to announce the acquisition of Pepceuticals, a UK producer of synthetic peptides with multi-kilogram GMP facilities and fill-finish capabilities designed to support customers from clinical trials to commercial supply.
